Beyond their primary function in weight management, GLP-1 receptor agonists, including semaglutide (known commercially as Ozempic), are showing promising and unexpected mental health benefits. A comprehensive study has revealed significant reductions in symptoms of depression and anxiety, alongside a notable decrease in psychiatric-related hospital visits among individuals using these medications. The research also indicated a substantial lowering of substance use disorders during treatment. Experts hypothesize that these positive mental health outcomes may be attributed to a combination of improved lifestyle factors resulting from weight loss and direct neurological effects within the brain.
Ozempic’s Surprising Benefits: Reducing Depression, Anxiety, and Addiction Risk
By Rupert Blackwood
Investigative journalist based in Sheffield, focusing on technology's impact on society. Rupert specializes in cybercrime's effect on communities, from online fraud targeting elderly residents to cryptocurrency scams. His reporting examines social media manipulation, digital surveillance, and how criminal networks operate in cyberspace. With expertise in computer systems, he connects technical complexity with real-world consequences for ordinary people